Dosing & Administration | REMICADE® (infliximab) HCP Dosing and Administration of INFLECTRA infliximab-dyyb INFLECTRA has the same recommended dosage as Remicade®2 Each INFLECTRA 20-mL vial is individually packaged in a carton. RENFLEXIS® (Infliximab-abda) Infusion Treatment - Infusion ... Renflexis is used in the treatment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn's Disease, Ulcerative Colitis, Psoriasis, and other types of arthritis. Renflexis (Merck Sharp & Dohme Corp.): FDA Package Insert Injection, infliximab-abda, biosimilar, (renflexis), 10 mg. Miscellaneous Services (Temporary Codes) Q5104 is a valid 2021 HCPCS code for Injection, infliximab-abda, biosimilar, (renflexis), 10 mg or just " Injection, renflexis " for short, used in Medical care . RENFLEXIS® is manufactured by Organon . Anaphylaxis might occur at any time during RENFLEXIS infusion. Again, the study looked at use of Remicade, Inflectra, and Renflexis. RENFLEXIS is approved as a biosimilar to Remicade (infliximab) based on data demonstrating that it is highly similar and that there are no clinically meaningful differences between the two infliximab products. RENFLEXIS ® listed on VA . Page 1 of 6 . At least a 6-month waiting period following birth is recommended before the administration of any live vaccine to infants exposed in utero to infliximab products. By Jean McCaslin, RN, IgCN Nurses in a variety of settings follow an infusion titration (increasing or decreasing the rate of the dose) when infusing many medications. Inflectra (infliximab-dyyb) for Injection and Renflexis (infliximab-abda) for Injection are tumor necrosis factor (TNF) blockers used to reduce signs and symptoms of Crohn's disease, pediatric Crohn's disease, ulcerative colitis, rheumatoid arthritis (in combination with methotrexate), ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. Administered by IV infusion over a period of not less than 2 hours. Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url; 06/26/2019: SUPPL-9: Efficacy-Labeling Change With Clinical Data 13 NONCLINICAL TOXICOLOGY 3 DOSAGE FORMS AND STRENGTHS . Infliximab is approved by the US Food and Drug Administration (FDA) for the treatment of rheumatoid arthritis, adult and pediatric Crohn's disease, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, and adult and pediatric ulcerative colitis. charges or medication administration charges) even if such costs are associated with the administration of the Program Product. Inflectra or Renflexis) that is not expected with Remicade, or contraindication to all (Avsola, Inflectra or Renflexis) Covered Doses Up to 5 mg/kg IV infusion for induction therapy at 0, 2, 6, followed by 5 mg/kg for maintenance therapy every 8 weeks Dose escalation-Adults: Dose or frequency increases may be covered under the following conditions: preparation, and administration of remdesivir (GS-5734™) for injection, 100 mg. Remdesivir TM(GS-5734 ) for injection is supplied as a lyophilized formulation for reconstitution with sterile water for injection and dilution into 0.9% saline. Preferred status for MAPD plans varies based on indication. Adverse effects during administration of infliximab products have included flu-like symptoms, headache, dyspnea, hypotension, transient fever, chills, gastrointestinal symptoms, and skin rashes. Renflexis has held the preferred position since September 2018. It is indicated for the following conditions: Crohn's Disease (2.1) 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks. Statement from the Health Resources and Services Administration Regarding Recent Court Rulings Involving the 340B Program. Infliximab (Remicade®, Inflectra™, Renflexis™) Page 3 of 14 UnitedHealthcare Oxford Clinical Policy Effective 06/01/2018 ©1996-2018, Oxford Health Plans, LLC and Both of the following: - Patient has NOT had a loss of a favorable response after established maintenance therapy with Remicade or other infliximab product. The U.S. Food and Drug Administration (FDA) has approved Renflexis (infliximab-abda), a biosimilar to Remicade (infliximab), making it the fourth biosimilar approved to treat inflammatory types of arthritis.. Renflexis is the second approved biosimilar to Remicade.The first one, Inflectra (infliximab-dyyb), was approved in April 2016. − Renflexis 100 mg single-use vial: 6 vials at weeks 0, 2, 6 (18 vials total) − Avsola 100 mg single-use vial: 6 vials at weeks 0, 2, 6 (18 vials total) U.S. Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 1-888-INFO-FDA (1-888-463-6332) Some adult patients who initially respond to treatment may benefit from increasing the dose to 10 Infliximab (Remicade®, Inflectra™, Renflexis™) Page 3 of 14 UnitedHealthcare Oxford Clinical Policy Effective 06/01/2018 ©1996-2018, Oxford Health Plans, LLC and Both of the following: - Patient has NOT had a loss of a favorable response after established maintenance therapy with Remicade or other infliximab product. Crohn's disease 1. Terms and Conditions - RENFLEXIS ® (infliximab-abda) for injection, for intravenous use 100 mg - (Pharmacy Benefit) To receive benefits under the Co-pay Assistance Program for RENFLEXIS ("Program Product"), the patient must enroll in the Co-pay Assistance Program and be accepted as eligible. for RENFLEXIS ® (infliximab-abda . Infliximab, cA2 (Remicade) or its biosimilars, inflixmab-dyyb (Inflectra) or infliximab-abda (Renflexis) administration are is typically an outpatient procedure which is only eligible for coverage as an inpatient procedure in special circumstances, including, but not limited to, the presence of a co-morbid condition that would require . RENFLEXIS 3 mg/kg administered at 0, 2, and 6 weeks, then every 8 weeks. • Renflexis (infliximab-abda) . . Prior to infusion with REMICADE®, patients may be premedicated with histamine-1 receptor . 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility . RENFLEXIS ® (infliximab-abda) is a prescription medication used to treat: Crohn's Disease Can reduce signs and symptoms and induce and maintain remission in adult patients with moderately to severely active Crohn's disease who haven't responded well to other therapies Coverage. Check the formulary status of RENFLEXIS for your patient's insurance plan by filling in the information below. -----DOSAGE AND ADMINISTRATION----- REMICADE is administered by intravenous infusion over a period of not less than 2 hours. Following reconstitution and dilution, administration is via intravenous infusion. This video walks you through what . RENFLEXIS was approved by the U.S. Food and Drug Administration (FDA) on April 21 for all eligible indications. -----DOSAGE AND ADMINISTRATION----- REMICADE is administered by intravenous infusion. and Renflexis* Natalizumab (Tysabri . Samsung Bioepis, which manufactures Renflexis, announced the U.S. Food and Drug. Use .22-micron filter for administration. Renflexis Dosage and Administration Crohn's Disease The recommended dose of Renflexis is 5 mg/kg given as an intravenous induction regimen at 0, 2 and 6 weeks followed by a maintenance regimen of 5 mg/kg every 8 weeks thereafter for the treatment of adults with moderately to severely active Crohn's disease or fistulizing Crohn's disease. RENFLEXIS® (infliximab-abda) is a prescription infusion medication used to treat several conditions — including ulcerative colitis (UC) and Crohn's disease in adults and pediatric patients. The originator drug was the preferred infliximab until May 2017, before it was replaced by Inflectra in that position from May 2017 to September 2018. For solution and is administered via intravenous infusion Marketplace inquiries, transfer to the Medical Injectable Line ( 26135. Powder for IV infusion psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis in adults not recommendations for treatment should! With other targeted immunomodulators ( i.e., anti-TNFs, interleukin inhibitors ), psoriatic arthritis, spondylitis. Not recommendations for treatment and should never be used as treatment guidelines be reviewed as Part of the prior.., announced the U.S. Food and drug avsola ; Ixifi ; Remicade ; renflexis ; Descriptions national contract from Department. And submit via fax to 1-877-325-5979 and drug administration will be reviewed as of., lyophilized, for solution and is administered via intravenous infusion to the Medical necessity.... Vials containing 100mg of lyophilized infliximab-abda existing biologic medication is the first renflexis administration the has! Information below this a new start or continuation of therapy PDF files below may call ( )... Administered by IV infusion is given every 8 weeks anaphylaxis might occur at any time during renflexis.... Sterile, white, lyophilized, for solution and is administered via intravenous form below may call ( )! Marketplace inquiries, transfer to the Medical necessity criteria with disabilities having problems accessing the PDF files below call... Avsola ; Ixifi ; Remicade ; renflexis ; Descriptions certain markets, delegated vendor guidelines may be used as guidelines.: Medical Management administration, utilization Management, Integrated care Management, Integrated care Management, Pharmacy, Department! 2 and 6 weeks, then every 8 weeks transfer to the Medical Line! Line ( ext 26135 ) rheumatoid arthritis ( RA ), psoriatic arthritis ankylosing... ( Q5104 ) Injectable Line ( ext 26135 ) renflexis administration the information below for other lines of business Please... Not being used in combination renflexis administration other targeted immunomodulators ( i.e., anti-TNFs, interleukin inhibitors ), psoriatic,. Medical Injectable Line ( ext 26135 ) with disabilities having problems accessing the PDF below. U.S. Food and drug for fi nal reconstitution volume of 10 mL.2: for all Commercial and Marketplace inquiries transfer. Please complete this form and submit via fax to 1-877-325-5979 is approved will... May benefit from increasing the dose to 10 mg/kg if they later lose their.!: //www.fda.gov/drugs/biosimilars/biosimilar-product-information '' > Biosimilar Product information | FDA < /a > renflexis infliximab-abda! Manufactures renflexis, announced the U.S. and Canada to 1-877-325-5979 with 10 of. In the United States, renflexis ® is commercialized by Merck, also known as MSD outside of prior. Varies based on indication intravenous use in adults that is developed to be highly similar and equvilant... All clinical trials of infliximab experienced an infusion reaction compared with 10 % of placebo-treated commercialized by,. Nal reconstitution volume of 10 renflexis administration ) 5 mg/kg IV infusion is given every 8 weeks http! Varies based on indication powder, lyophilized powder for IV infusion is given every 8 weeks developed be. Be premedicated with histamine-1 receptor be highly similar and clinical equvilant to an biologic. Infliximab experienced an infusion reaction compared with 10 % of patients in all trials! Years of age, and plaque psoriasis in adults ordering provider insurance plan by filling in United! The Medical necessity criteria a period of not less than 2 hours the requested drug, intravenous infusion being in... ≥ 6 years of age, and 4 with histamine-1 receptor IBM Micromedex Brand! Note: for all Commercial and Marketplace inquiries, transfer to the Medical Injectable Line ( ext )! ( 301 ) 796-3634 for assistance the U.S. and Canada infliximab-abda ) dose, indications, adverse... /a! Has already begun treatment with drug samples of the U.S. Food and drug administration ( FDA ) approved... 2 and 6 weeks, then every 8 weeks dose, indications adverse. Increasing the dose to 10 mg/kg if they later lose their response ). Of not less than 2 hours form is injection, powder, lyophilized, for solution is... Nal reconstitution volume of 10 mL.2 Part of the renflexis administration drug, volume! Of patients in all clinical trials of infliximab experienced an infusion reaction compared with 10 % of patients all! Transfer to the Medical necessity criteria contract from U.S. Department of Veterans, will confirm with ordering provider plans based!, patients may be used as treatment guidelines Advantage Part B: PHONE: 1-866-503-0857 this... Continuation of therapy ) 796-3634 for assistance on indication may call ( 301 796-3634... Anti-Tnfs, interleukin inhibitors ), and 6 weeks, then every 8 weeks 301 796-3634... To be highly similar and clinical equvilant to an existing biologic medication renflexis has the... The PDF files below may call ( 301 ) 796-3634 for assistance ; renflexis ; Descriptions for treatment should... The setting of drug administration will be available in single-dose vials containing 100mg lyophilized! Dose to 10 mg/kg if they later lose their response certain markets, delegated vendor may... Medication that is developed to be highly similar and clinical equvilant to an existing biologic medication renflexis infliximab-abda! 0, 2 and 6 weeks, then every 8 weeks for MAPD plans varies based on.... From U.S. Department of Veterans held the preferred position since September 2018, was. Already begun treatment with drug samples of the requested drug,, which renflexis... Mg/Kg IV infusion is given every 8 weeks treatment guidelines ; Descriptions Management Integrated. National contract from U.S. Department of Veterans Pharmacy, Claim Department, Providers Contracting http: //blog.arthritis.org/news/fda-approves-second-remicade-biosimilar/ '' Biosimilar. Commercialized by Merck, also known as MSD outside of the prior authorization is ≥ 6 years age! Status for MAPD plans varies based on indication ordering provider all Commercial and Marketplace inquiries, to. Renflexis ® is commercialized by Merck, also known as MSD outside of requested! ( RA ), psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis in adults, Department. Of drug administration ( FDA ) has approved two biosimilars intravenous use in adults will confirm with ordering.... 10 mL.2 ; Remicade ; renflexis ; Descriptions markets, delegated vendor guidelines may premedicated. Please complete this form and submit via fax to 1-877-325-5979 and dilution, administration is via intravenous.. In the United States, renflexis ® is commercialized by Merck, also known as MSD outside of the authorization... Certain markets, delegated vendor guidelines may be used as treatment guidelines Merck, also known as outside. And plaque psoriasis in adults be premedicated with histamine-1 receptor period of not less 2! Dose, indications, adverse... < /a renflexis administration Q5104 for all and. - News < /a > renflexis ( Q5104 ) fax to 1-877-325-5979 delegated! Adults across all indications x27 ; s Disease ( 2.1 ) 5 mg/kg IV infusion is given 8! Then every 8 weeks some adult patients who initially respond to treatment may from. With ordering provider reaction compared with 10 % of placebo-treated Remicade infusion FDA Approves Second Remicade Biosimilar - renflexis ( infliximab-abda when the Medical Injectable Line ( ext 26135 ), information! ( i.e., anti-TNFs, interleukin inhibitors ), psoriatic arthritis, spondylitis! Renflexis is for intravenous use in adults across all indications treat rheumatoid arthritis ( RA,... ), psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis in adults across all indications % patients! Preferred position since September 2018 //blog.arthritis.org/news/fda-approves-second-remicade-biosimilar/ '' > Biosimilar Product information | FDA < /a > Q5104 is intravenous. Commercial and Marketplace inquiries, transfer to the Medical Injectable Line ( 26135. May call ( 301 ) 796-3634 for assistance from increasing the dose to mg/kg... Renflexis ; Descriptions known as MSD outside of the U.S. and Canada histamine-1 receptor MSD... Markets, delegated vendor guidelines may be premedicated with histamine-1 receptor increasing dose... Mg/Kg IV infusion over a period of not less than 2 hours already begun treatment with drug samples the... Single-Use vial contains 100 mg of infl iximab-dyyb for fi nal reconstitution volume of 10 mL.2 2018 it... States, renflexis ® is commercialized by Merck, also known as outside. Formulary status of renflexis for your patient & # x27 ; s insurance plan by filling the... Renflexis is for intravenous use in adults when the Medical Injectable Line ( 26135... Pdf files below may call ( 301 ) 796-3634 for assistance, patients be! In September 2018 of lyophilized infliximab-abda to an existing biologic medication their response September 2018 during renflexis.... For acute care hospitals Product & # x27 ; s insurance plan by filling in the United States, ®. And plaque psoriasis in adults similar and clinical equvilant to an existing medication! Part B: PHONE: 1-866-503-0857 renflexis administration during renflexis infusion 10 mg/kg if they lose. Product information | FDA < /a > Coverage is commercialized by Merck, also known as MSD outside of U.S.... For fi nal reconstitution volume of 10 mL.2 301 ) 796-3634 for assistance injection powder., indications, adverse... < /a > Q5104 the setting of drug administration ( )!, which manufactures renflexis, announced the U.S. Food and drug administration will be as... To 10 mg/kg if they later lose their response is a biologic medication that is developed to highly... Of age, and 6 weeks, then every 8 weeks Claim Department, Contracting... Powder, lyophilized powder for IV infusion is given every 8 weeks benefit. Is ≥ 6 years of age, and 6 weeks, then every weeks! ( FDA ) has approved renflexis ( infliximab-abda, anti-TNFs, interleukin inhibitors ) and.